Evidence map›Paper›PMID 42059134›Full record

ArticleJournal of medicinal chemistry2026

Development of Biphenyl-Substituted Uracil-Based Hydroxamic Acids (UBHAs) as Potent HDAC Inhibitors with Pro-Apoptotic Activity in Leukemia and Prostate Cancer Cells.

Francesco Fiorentino, Giulio Bontempi, Federica Michetti, Valeria Pecci, Emanuele Fabbrizi, Daniela Passeri, Letizia Corsetti, Valentina Farini, Fabrizio Casano, Antimo Gioiello and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Francesco FiorentinoDepartment of Biochemical Sciences, Sapienza University of Rome, Piazzale Aldo 5, 00185 Rome, Italy.ORCID 0000-0003-3550-1860
Giulio BontempiDepartment of Molecular Medicine, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy.
Federica MichettiDepartment of Molecular Medicine, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy.
Valeria PecciDepartment of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, Largo Francesco Vito, 1, 00168 Rome, Italy.
Emanuele FabbriziDepartment of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo 5, 00185 Rome, Italy.
Daniela PasseriTES Pharma S.r.l., Via P. Togliatti 20, Corciano, 06073 Perugia, Italy.
Letizia CorsettiDepartment of Physiology and Pharmacology "V. Erspamer", Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy.
Valentina FariniPreclinical Models and New Therapeutic Agents Unit, IRCCS-Regina Elena National Cancer Institute, Rome 00144, Italy.
Fabrizio CasanoDepartment of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo 5, 00185 Rome, Italy.
Antimo GioielloDepartment of Pharmaceutical Sciences, University of Perugia, Via del Liceo 1, 06122 Perugia, Italy.
Antonella Di SottoDepartment of Physiology and Pharmacology "V. Erspamer", Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy.
Roberto PellicciariTES Pharma S.r.l., Via P. Togliatti 20, Corciano, 06073 Perugia, Italy.
Donatella Del BufaloPreclinical Models and New Therapeutic Agents Unit, IRCCS-Regina Elena National Cancer Institute, Rome 00144, Italy.
Daniela TrisciuoglioInstitute of Molecular Biology and Pathology, National Research Council (CNR), Via degli Apuli, 4, Rome 00185, Italy.
Simona NanniDepartment of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, Largo Francesco Vito, 1, 00168 Rome, Italy.
Raffaele StrippoliDepartment of Molecular Medicine, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy.
Antonello MaiDepartment of Drug Chemistry and Technologies, Sapienza University of Rome, Piazzale Aldo 5, 00185 Rome, Italy.ORCID 0000-0001-9176-2382
Dante RotiliDepartment of Science, Roma Tre University, Viale Marconi 446, 00146 Rome, Italy.ORCID 0000-0002-8428-8763

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Histone deacetylases (HDACs) regulate transcription by removing acetyl groups from lysines, and their dysregulation promotes cancer. Clinically approved HDAC inhibitors show limited isoform selectivity, toxicity, and modest efficacy in solid tumors. We therefore designed and synthesized uracil-based hydroxamic acids (UBHAs) bearing systematic cap group and linker modifications. Several compounds achieved nanomolar inhibition, particularly against HDAC6, and reduced activity toward class I isoforms. Structure-activity relationships highlight that

Indexed as

Antineoplastic AgentsApoptosisBiphenyl CompoundsHistone Deacetylase InhibitorsHydroxamic AcidsLeukemiaProstatic NeoplasmsUracilCell Line, TumorCell ProliferationCell SurvivalHistone DeacetylasesHumansMaleStructure-Activity RelationshipAntineoplastic AgentsbiphenylBiphenyl CompoundsHistone Deacetylase InhibitorsHistone DeacetylasesHydroxamic AcidsUracil

Identifiers

PMID42059134
PMCPMC13181782

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.